Blog, News, Companies, blood glucose meters, oral, Nasal, transdermal, insulin,type 2, pancreatic islet cells, Macular Edema, Ulcers, continuous glucose monitoring, HbA1c, hemoglobin A1C, oral anti-diabetic agent, data management system, Hypoglycemia, glucagon, therapeutic vaccine, peripheral neuropathy, Neuropathic pain, diabetes mellitus, type 1, foot ulcers, test strip, glycemic control, nephropathy, resistant, sensitizers, foot infections, sensor, retinopathy, non-invasive monitor...
Jan. 17 , 2008 - Immunosyn Corporation (OTC Bulletin Board: IMYN ) announced that the first phase of a formal "Proof of Concept Trial" for the biopharmaceutical SF-1019 has been successfully completed in Europe for treatment of Diabetic Ulcers ... 
Argyll Biotechnologies is the developer and licensor of SF-1019, for which Immunosyn has been granted the world-wide rights to market, sell and distribute under an exclusive license agreement... [PDF] Immunosyn' s Press Release-
